Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
10:55am, Friday, 09'th Aug 2024
The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
10:05pm, Tuesday, 06'th Aug 2024
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Execu
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
09:02pm, Tuesday, 06'th Aug 2024
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
07:46pm, Tuesday, 06'th Aug 2024
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago.
Supernus Announces Second Quarter 2024 Financial Results
04:06pm, Tuesday, 06'th Aug 2024
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
04:30pm, Thursday, 01'st Aug 2024
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
04:13pm, Tuesday, 23'rd Jul 2024
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
01:58pm, Friday, 19'th Jul 2024
When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
04:25pm, Thursday, 30'th May 2024
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
04:05pm, Thursday, 23'rd May 2024
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
12:58pm, Thursday, 23'rd May 2024
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors ar
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
07:40pm, Thursday, 16'th May 2024
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors ar
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
08:28pm, Wednesday, 08'th May 2024
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executiv
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
08:01pm, Wednesday, 08'th May 2024
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
